Notably, preclinical studies suggested that combining these nanoparticles with anti–PD-L1 enhanced tumor control and delineated a promising therapeutic approach using anti–PD-L1–conjugated nanocarriers for aggressive CRC (Júnior et al., 2023). This evidence concerns the gene CD274 and colorectal carcinoma.